Reading Time: 2 minutes
Illumina (ILMN, i) provides a key technology for analyzing human DNA with NovaSeq X, particularly in cancer testing and the development of targeted therapies. More than 95 devices were added in the second quarter alone. Approximately 74% of revenues come from consumables needed by customers for each examination. This convinces me: The more devices installed and utilized, the stronger the recurring revenues can grow. Clinical demand is already picking up significantly. The BioInsight platform, presented on October 14, opens up an additional software...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
